

30 June 2009

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products listed in the Invitation to Tender dated 23 December 2008.

Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly.

Product Notification Forms

Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm **10th July 2009**. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp.

2007/08 Tender

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

Chemical Name	Line Item
Piperacillin Sodium with Tazobactam Sodium	Inj 4 g with tazobactam sodium 500 mg
Zidovudine (AZT)	Oral liq 10 mg per ml

2008/09 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on **1 August 2009** and Sole Subsidised Supply commences on **1 November 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current Subsidy	New tender subsidy	Sole supply brand (Supplier)
Atenolol	Tab 50 mg; 500 tablets, bottle	\$6.50	\$6.18	Pacific Atenolol (Mylan)
Atenolol	Tab 100 mg; 500 tablets, bottle	\$11.30	\$10.73	Pacific Atenolol (Mylan)
Nevirapine	Oral suspension 10 mg per ml; 240 ml, bottle	\$134.55	\$134.55	Viramune (Boehringer Ingelheim)
Nevirapine	Tab 200 mg; 60 tablets, blister	\$319.80	\$319.80	Viramune (Boehringer Ingelheim)

2. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 August 2009**, reference pricing of non-tender winning brand will occur on **1 October 2009** and Sole Subsidised Supply commences on **1 January 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Calamine	Crn, aqueous, BP; 100 ml, pot	\$3.02	\$2.78	healthE (Jaychem)	ABM (ABM)
Calamine	Lotn BP, 2,000 ml, bottle	\$19.44	\$16.70	API (API Consumers)	ABM (ABM)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes (where applicable) for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on **1 August 2009**; DV Limits and DV Pharmaceuticals will apply from **1 October 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Atenolol	Tab 50 mg; 500 tablets, bottle	Pacific Atenolol (Mylan)	\$6.18	1%	Anselol (Douglas) Apo-Atenolol (Apotex) Atehexal (Novartis) Global Atenolol (Apotex)
Atenolol	Tab 100 mg; 500 tablets, bottle	Pacific Atenolol (Mylan)	\$10.73	1%	Anselol (Douglas) Apo-Atenolol (Apotex) Atehexal (Novartis) Global Atenolol (Apotex)
Epirubicin *	Inj 2 mg per ml, 5 ml; 1 injection, vial	Epirubicin Ebewe (InterPharma)	\$25.00	1%	Hospira (Hospira) Pharmorubicin (Pfizer)
Epirubicin *	Inj 2 mg per ml, 25 ml; 1 injection, vial	Epirubicin Ebewe (InterPharma)	\$87.50	1%	Hospira (Hospira) Pharmorubicin (Pfizer)
Epirubicin *	Inj 2 mg per ml, 50 ml; 1 injection, vial	Epirubicin Ebewe (InterPharma)	\$155.00	1%	Hospira (Hospira) Pharmorubicin (Pfizer)
Epirubicin *	Inj 2 mg per ml, 100 ml; 1 injection, vial	Epirubicin Ebewe (InterPharma)	\$310.00	1%	Hospira (Hospira) Pharmorubicin (Pfizer)
Nevirapine	Oral suspension 10 mg per ml; 240 ml, bottle	Viramune (Boehringer Ingelheim)	\$134.55	1%	(B)
Sodium hyaluronate	Ophthalmic inj 14 mg per ml; 1 injection, syringe	Healon GV (Advanced Medical Optics)	\$50.00	1%	(B)
Sodium hyaluronate	Ophthalmic soln 10 mg per ml; 1 injection, syringe	Healon (Advanced Medical Optics)	\$35.00	1%	Provisc (Mylan)

* Note the pricing of Epirubicin Ebewe in Section B of the Pharmaceutical Schedule for PCT and ECP preparations will be amended accordingly

4. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 August 2009** and DV Limits and DV Pharmaceuticals will apply from **1 October 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Nevirapine	Tab 200 mg; 60 tablets, blister	Viramune (Boehringer Ingelheim)	\$319.80	1%	(B)
Paraffin	Yellow soft; 10 g, tube	API (API Consumer)	\$1.04	1%	Dal (MidWest Pharmaceuticals) Orion (Orion)

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 23 December 2008.

The decisions were as follows:

Chemical Name	Line Item
Aciclovir	Inj 500 mg
Aciclovir	Inj 1,000 mg
Calcium Carbonate with Aminoacetic Acid	Tab 400-420 mg with aminoacetic acid 180 mg
Calcium Gluconate	Inj 10%, 10 ml
Clomiphene Citrate	Tab 50 mg
Cocaine	Soln 4%, 2 ml BP
Epirubicin	Inj 1 mg per ml, 5 ml
Epirubicin	Inj 2 mg per ml, 2 ml
Epirubicin	Inj 2 mg per ml, 10 ml
Levodopa with Benserazide	Cap 100 mg with benserazide 25 mg
Levodopa with Benserazide	Cap 200 mg with benserazide 50 mg
Levodopa with Benserazide	Cap 50 mg with benserazide 12.5 mg
Levodopa with Benserazide	Cap long-acting 100 mg with benserazide 25 mg
Levodopa with Benserazide	Tab dispersible 50 mg with benserazide 12.5 mg
Lisinopril	Tab 20 mg with hydrochlorothiazide 12.5 mg
Pyrantel Embonate	Oral suspension
Pyrantel Embonate	Tab
Sodium Hyaluronate	Inj 10 mg per ml, 0.35 ml; and inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.4 ml
Sodium Hyaluronate	Inj 10 mg per ml, 0.5 ml; and inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.55 ml
Travoprost	Eye drops 0.004%
Vincristine Sulphate	Inj 1 mg per ml, 1 ml
Vincristine Sulphate	Inj 1 mg per ml, 2 ml
Vitamin B Complex (BPC, strong)	Tab
Vitamins (BPC cap strength)	Tab

For the remaining products on the Invitation to Tender dated 21 December 2007 and the Invitation to Tender dated 23 December 2008 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock.

We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.